000513 丽珠集团
已收盘 04-17 15:00:00
资讯
新帖
简况
丽珠集团最新公告：JP-1366片获临床试验批准
证券之星 · 04-10
丽珠集团最新公告：JP-1366片获临床试验批准
每周股票复盘：丽珠集团（000513）将召开2025年度业绩说明会
证券之星 · 04-05
每周股票复盘：丽珠集团（000513）将召开2025年度业绩说明会
丽珠集团（000513）发布2025年度业绩说明会公告，4月02日股价上涨0.49%
证券之星 · 04-02
丽珠集团（000513）发布2025年度业绩说明会公告，4月02日股价上涨0.49%
【机构调研记录】中信保诚基金调研丽珠集团、聚辰股份等3只个股（附名单）
证券之星 · 03-30
【机构调研记录】中信保诚基金调研丽珠集团、聚辰股份等3只个股（附名单）
东吴证券：给予丽珠集团买入评级
证券之星 · 03-28
东吴证券：给予丽珠集团买入评级
丽珠集团（000513）披露获得药物临床试验批准通知书，3月27日股价上涨2.56%
证券之星 · 03-27
丽珠集团（000513）披露获得药物临床试验批准通知书，3月27日股价上涨2.56%
长护险全面推行；我国已稳步迈入结核病中低流行国家行列
21世纪经济报道 · 03-27
长护险全面推行；我国已稳步迈入结核病中低流行国家行列
开源证券：给予丽珠集团买入评级
证券之星 · 03-26
开源证券：给予丽珠集团买入评级
丽珠集团最新公告：注射用布瑞哌唑微球获临床试验批准
证券之星 · 03-26
丽珠集团最新公告：注射用布瑞哌唑微球获临床试验批准
丽珠集团（000513）2025年年报简析：增收不增利，盈利能力上升
证券之星 · 03-26
丽珠集团（000513）2025年年报简析：增收不增利，盈利能力上升
丽珠集团最新公告：2025年净利润20.23亿元，同比下降1.84%
中金财经 · 03-24
丽珠集团最新公告：2025年净利润20.23亿元，同比下降1.84%
丽珠集团高管“大换血”：增长失速下的无奈与豪赌
新浪证券 · 03-20
丽珠集团高管“大换血”：增长失速下的无奈与豪赌
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
证券之星 · 03-06
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
丽珠集团（000513）发布关于为子公司提供担保的进展公告，3月3日股价下跌0.92%
证券之星 · 03-03
丽珠集团（000513）发布关于为子公司提供担保的进展公告，3月3日股价下跌0.92%
每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保
证券之星 · 02-08
每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保
丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%
证券之星 · 02-04
丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%
丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%
证券之星 · 02-02
丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%
【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）
证券之星 · 01-23
【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）
丽珠集团：丽珠生物拥有三大业务板块
证券日报网 · 01-22
丽珠集团：丽珠生物拥有三大业务板块
每周股票复盘：丽珠集团（000513）回购股份注销完成
证券之星 · 01-11
每周股票复盘：丽珠集团（000513）回购股份注销完成
公司概况
公司名称：
丽珠医药集团股份有限公司
所属行业：
医药制造业
上市日期：
1993-10-28
主营业务：
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备。截至2025年12月31日，公司累计拥有国内外有效授权专利991项，其中发明专利523项。
发行价格：
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":33.79,"timestamp":1776409434000,"preClose":34.31,"halted":0,"volume":6589937,"delay":0,"changeRate":-0.0152,"floatShares":568000000,"shares":888000000,"eps":2.2361,"marketStatus":"已收盘","change":-0.52,"latestTime":"04-17 15:00:00","open":34.2,"high":34.2,"low":33.65,"amount":223000000,"amplitude":0.016,"askPrice":33.8,"askSize":73,"bidPrice":33.79,"bidSize":218,"shortable":0,"etf":0,"ttmEps":2.2361,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":34.31,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":37.74,"lowLimit":30.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":887907171,"isCdr":false,"pbRate":2.19,"roa":"--","peRate":15.111131,"roe":"14.67%","epsLYR":2.27,"committee":0.570445,"marketValue":30002000000,"turnoverRate":0.0116,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-20。","hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":28.94,"timestamp":1776413294004,"preClose":29.34,"halted":0,"volume":828065,"delay":0,"premium":"-25.56"},"floatMarketCap":19197000000},"requestUrl":"/m/hq/s/000513/wiki","defaultTab":"wiki","newsList":[{"id":"2626196528","title":"丽珠集团最新公告：JP-1366片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626196528","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626196528?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:50","pubTimestamp":1775814633,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告称，公司近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意公司申报的JP-1366片开展“与适当的抗生素联用以根除幽门螺杆菌”适应症的临床试验。JP-1366片是一款创新钾离子竞争性酸阻滞剂(P-CAB)，具有起效迅速、抑酸作用强且持久的特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000031078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000513","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616336","title":"每周股票复盘：丽珠集团（000513）将召开2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616336","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616336?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:43","pubTimestamp":1775324593,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，丽珠集团报收于34.43元，较上周的34.07元上涨1.06%。本周关注点公司公告汇总：丽珠集团将于2026年4月10日召开2025年度业绩说明会 公司公告汇总：截至2026年3月31日，丽珠集团H股与A股股本及已发行股份无变动 公司公告汇总H股公告：证券变动月报表丽珠医药集团股份有限公司提交截至2026年3月31日的证券变动月报表，显示公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0239","BK0188","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624236500","title":"丽珠集团（000513）发布2025年度业绩说明会公告，4月02日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624236500","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624236500?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:57","pubTimestamp":1775141831,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，丽珠集团报收于35.07元，较前一交易日上涨0.49%，最新总市值为311.39亿元。丽珠医药集团股份有限公司于2026年4月2日披露《关于召开2025年度业绩说明会的公告》。公告显示，公司已于2026年3月25日在巨潮资讯网披露《2025年年度报告》及其摘要；为加强与投资者沟通，公司定于2026年4月10日15:00至17:00通过全景网“投资者关系互动平台”举办2025年度业绩说明会，采用网络远程方式举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","000513","BK0239","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623136982","title":"【机构调研记录】中信保诚基金调研丽珠集团、聚辰股份等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2623136982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623136982?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:01","pubTimestamp":1774828882,"startTime":"0","endTime":"0","summary":"2）聚辰股份 调研纪要：2025年公司实现营业收入12.21亿元，较上年同期增长18.77%，归母净利润为3.64亿元，同比分别增长25.25%，均创下历史同期最好成绩。汽车级EEPROM芯片导入全球多家Tier1供应商，覆盖全球前20大中16大及国内全部前20大汽车品牌。中信保诚基金成立于2005年，截至目前，资产管理规模1774.53亿元，排名43/212；资产管理规模957.55亿元，排名50/212；管理公募基金数209只，排名35/212；旗下公募基金经理25人，排名58/212。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000001753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","688123","BK0239","LU0211331839.USD","LU0575583348.USD","LU1880383366.USD","LU0048597586.USD","02378","LU1015430645.USD","BK0187","BK0188","000513","BK1184","BK0214","LU0251144936.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622171388","title":"东吴证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622171388","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622171388?lang=zh_cn&edition=full","pubTime":"2026-03-28 14:30","pubTimestamp":1774679432,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,刘若彤近期对丽珠集团进行研究并发布了研究报告《2025年年报点评：业绩符合预期，加速创新转型，布局国际化出海》，给予丽珠集团买入评级。我们长期看好公司主业稳健，战略布局多元化，创新属性产品价值加速兑现，大力拓展海外国际市场，且估值仍处于低位，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为55.67。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032800016269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622844757","title":"丽珠集团（000513）披露获得药物临床试验批准通知书，3月27日股价上涨2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622844757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622844757?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:21","pubTimestamp":1774603300,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，丽珠集团报收于34.07元，较前一交易日上涨2.56%，最新总市值为302.51亿元。该股当日开盘33.0元，最高34.16元，最低32.99元，成交额达2.51亿元，换手率为1.3%。丽珠医药集团股份有限公司全资子公司珠海市丽珠微球科技有限公司于近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。截至目前，该品种累计研发投入约752.64万元，国内尚无布瑞哌唑长效制剂获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700036276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0187","000513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622157858","title":"长护险全面推行；我国已稳步迈入结核病中低流行国家行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2622157858","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622157858?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:31","pubTimestamp":1774575097,"startTime":"0","endTime":"0","summary":"政策动向8部门印发《加快建立长期护理保险制度实施方案》3月26日，国家医保局、民政部、财政部、人力资源社会保障部、农业农村部、国家卫生健康委、国家税务总局、中国残疾人联合会今日印发《加快建立长期护理保险制度实施方案》。单位职工参加长期护理保险由用人单位和职工个人共同缴费，与职工基本医疗保险费共同缴纳。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686638836.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686638836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1064131003.USD","SY","BK0196","BK4563","BK0188","ADC","000513","BK0187","BK4503","002773","BK4080","BK0197","300497","LU1064130708.USD","BK4231","BK4077","BK0239","LU2148510915.USD","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985614","title":"开源证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622985614?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:16","pubTimestamp":1774520191,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,刘艺近期对丽珠集团进行研究并发布了研究报告《公司信息更新报告：公司基本盘表现稳健，创新国际化进展加快》，给予丽珠集团买入评级。丽珠集团差异化创新管线快速推进，我们认为其估值有望进一步提升。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为55.67。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600035534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622399855","title":"丽珠集团最新公告：注射用布瑞哌唑微球获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622399855","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622399855?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:50","pubTimestamp":1774518620,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告称，公司全资子公司珠海市丽珠微球科技有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意其自主研发的注射用布瑞哌唑微球(化学药品2.2类改良型新药)开展用于成人精神分裂症的临床试验。该药为长效缓释制剂，拟定给药方式为每月一次肌肉注射，旨在提升患者依从性、降低复发率。截至公告日，该药品累计研发投入约752.64万元。目前国内尚无布瑞哌唑长效制剂获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600032665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0187","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002510","title":"丽珠集团（000513）2025年年报简析：增收不增利，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002510","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622002510?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:06","pubTimestamp":1774476409,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期丽珠集团发布2025年年报。截至本报告期末，公司营业总收入120.2亿元，同比上升1.76%，归母净利润20.23亿元，同比下降1.84%。本报告期丽珠集团盈利能力上升，毛利率同比增幅0.68%，净利率同比增幅2.81%。持有丽珠集团最多的基金为华夏国证疫苗与生物科技指数发起A，目前规模为0.35亿元，最新净值0.6108，较上一交易日上涨0.98%，近一年下跌7.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621757098","title":"丽珠集团最新公告：2025年净利润20.23亿元，同比下降1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757098","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621757098?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:58","pubTimestamp":1774360685,"startTime":"0","endTime":"0","summary":"丽珠集团公告，2025年营业收入120.2亿元，同比增长1.76%。净利润20.23亿元，同比下降1.84%。公司董事会决议通过的本报告期利润分配预案为：向本公司全体股东每10股派发现金股利人民币14.3元(含税)，不送红股，不以公积金转增股本。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260324/32094922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620678950","title":"丽珠集团高管“大换血”：增长失速下的无奈与豪赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620678950","media":"新浪证券","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620678950?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:47","pubTimestamp":1773996420,"startTime":"0","endTime":"0","summary":"近日，一则人事变动公告将老牌药企丽珠医药推至聚光灯下。四位核心高管同日递交辞呈，三位服务企业超过三十年的“老将”因龄退场，年仅38岁的85后刘大平接棒总裁职务。表面看是一次例行新老交替，实则折射出一家陷入增长焦虑的药企，正试图通过人事“大换血”来撕开困局的急迫心情。对于丽珠医药而言，这既是一场迫不得已的自我革命，也是一次押注未来的豪赌。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-20/doc-inhrrrer7992982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000513","BK0187","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617365106","title":"健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617365106","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617365106?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:33","pubTimestamp":1772807597,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，健康元报收于11.19元，较前一交易日上涨2.85%，最新总市值为204.72亿元。健康元药业集团股份有限公司近日发布关于控股子公司丽珠集团拟公开收购越南IMP公司股权的进展公告。公告显示，健康元于2025年5月22日召开董事会，审议通过控股子公司丽珠集团拟通过境外全资附属公司LIAN SGP收购越南上市公司Imexpharm Corporation64.81%股份的议案。因交易触发公开要约收购义务，LIAN SGP拟向IMP全体股东发出收购要约。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600380","BK0239","BK0077","BK0114","FVNmain","BK0046","000513","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616326030","title":"丽珠集团（000513）发布关于为子公司提供担保的进展公告，3月3日股价下跌0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616326030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616326030?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:26","pubTimestamp":1772547980,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，丽珠集团报收于34.38元，较前一交易日下跌0.92%，最新总市值为305.26亿元。近日，丽珠医药集团股份有限公司发布《关于为子公司提供担保的进展公告》。公司对丽珠单抗持股66.54%，其年度担保上限为21亿元，截至2026年2月28日，实际担保余额为85,847.85万元。被担保人非失信被执行人，公司对外担保余额占最近一期经审计净资产的11.71%，均为对子公司担保，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0188","000513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609525337","title":"每周股票复盘：丽珠集团（000513）为子公司提供9.1亿元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525337?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:46","pubTimestamp":1770486374,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，丽珠集团报收于35.46元，较上周的34.96元上涨1.43%。本周关注点公司公告汇总：丽珠集团为子公司丽珠合成和丽珠单抗提供合计9.1亿元担保。公司公告汇总H股公告：证券变动月报表丽珠医药集团股份有限公司提交截至2026年1月31日的证券变动月报表，显示公司H股和A股的法定/注册股本及已发行股份均无变动。公司对丽珠单抗持股66.54%，其年度担保上限为21亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000513","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608607013","title":"丽珠集团（000513）披露为子公司提供担保进展公告，2月4日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608607013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608607013?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:22","pubTimestamp":1770214940,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，丽珠集团报收于35.49元，较前一交易日上涨1.4%，最新总市值为315.12亿元。近日，丽珠医药集团股份有限公司披露《关于为子公司提供担保的进展公告》。公告显示，公司于2026年1月为全资子公司丽珠合成和控股子公司丽珠单抗提供担保。公司对丽珠单抗持股66.54%，其年度担保上限为21亿元。截至2026年1月31日，公司对外担保余额为174,476.12万元，占归属于母公司净资产的12.59%，均为对子公司的担保，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","000513","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608860194","title":"丽珠集团（000513）披露证券变动月报表，2月2日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608860194?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:53","pubTimestamp":1770043995,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，丽珠集团报收于34.54元，较前一交易日下跌1.2%，最新总市值为306.68亿元。该股当日开盘34.81元，最高35.11元，最低34.47元，成交额达2.3亿元，换手率为1.16%。近日，丽珠医药集团股份有限公司披露截至2026年1月31日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本及已发行股份均无变动。A股于深圳证券交易所上市，股份代号000513，上月底结存及本月底结存均为588,100,054股，每股面值人民币1元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000513","BK0188","BK0187","BK0239","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605948446","title":"【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2605948446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605948446?lang=zh_cn&edition=full","pubTime":"2026-01-23 08:12","pubTimestamp":1769127128,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月22日披露的机构调研信息，宝盈基金近期对3家上市公司进行了调研，相关名单如下：1）丽珠集团 个股亮点：公司已正式完成DeepSeek-R1 671B“满血”版的部署应用，成为国内首批将千亿参数级AI模型引入核心业务的医药企业2）ST绝味 调研纪要：公司现处于“其他风险警示”期间，将在中国证监会处罚决定满12个月且完成财务追溯重述后，申请撤销风险警示。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300005860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603517","BK0239","BK0238","000513","BK0028","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605498879","title":"丽珠集团：丽珠生物拥有三大业务板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2605498879","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605498879?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:08","pubTimestamp":1769080080,"startTime":"0","endTime":"0","summary":"证券日报网1月22日讯，丽珠集团在接受调研者提问时表示，丽珠生物是健康元和丽珠集团共同唯一的生物药平台，拥有三大主要业务板块：自免领域、生殖领域和疫苗领域。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260122/c674231665.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260122/c674231665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0187","000513","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602353988","title":"每周股票复盘：丽珠集团（000513）回购股份注销完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2602353988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602353988?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:25","pubTimestamp":1768076709,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，丽珠集团报收于36.58元，较上周的34.46元上涨6.15%。本周，丽珠集团1月7日盘中最高价报37.42元。本周关注点公司公告汇总：丽珠集团完成回购A股股份注销，共注销16,193,259股，占注销前总股本的1.79%。本次注销后，公司已发行A股股份总数由604,293,313股减少至588,100,054股。H股公告：证券变动月报表丽珠医药集团股份有限公司截至2025年12月31日，普通股H股法定/注册股本无变动，普通股A股因购回股份减少16,193,259股，导致法定/注册股本相应减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK0188","000513","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776563641163,"stockEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":-0.0373},{"period":"3month","weight":-0.0564},{"period":"6month","weight":-0.0958},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0194}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"58201人(较上一季度增加1.85%)","perCapita":"9761股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"88790万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药及中间体产品、中药制剂产品、生物制品、诊断试剂及设备。截至2025年12月31日，公司累计拥有国内外有效授权专利991项，其中发明专利523项。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}